Endo International plc (NASDAQ:ENDP) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -0.06% to 15.86 with around 4.3 Million shares have changed hands in this session. Endo International plc (ENDP) released that its operating company, Par Pharma, has begun shipping mycophenolatemofetil hydrochloride for injection, which is the generic version of Roche’s CellCept.
Mycophenolatemofetil hydrochloride for injection is packaged in cartons of four 500 mg single dose vials.Endo International noted that, according to IMS Health data, U.S. sales of injectable CellCept were approximately $42 million for the 12 months ended October 31, 2016. The stock is going forward its fifty-two week low with 26.27% and lagging behind from its 52-week high price with -75.11%.
Similar, the positive performance for the quarter recorded as -21.87% and for the year was -73.40%, while the YTD performance remained at -74.09%. ENDP has Average True Range for 14 days of 0.98.
Synchronoss Technologies, Inc. (NASDAQ:SNCR) [Trend Analysis] retains strong position in active trade, as shares scoring -13.08% to $42.59 in a active trade session, while looking at the shares volume, around 2.84 Million shares have changed hands in this session. Synchronoss Technologies, Inc. (SNCR) and Intralinks Holdings, Inc. (IL) released they have entered into a definitive agreement for Synchronoss to acquire Intralinks for approximately $821 million in equity value.
Intralinks Holdings is a global content collaboration company that provides cloud-based solutions to control the sharing, distribution and management of high value content within and across organizations according to the highest-level of security and the most stringent compliance regulations. Synchronoss will commence a cash tender offer to acquire all of the outstanding common stock of Intralinks for $13 per share.Ron Hovsepian, CEO of Intralinks, is expected to be appointed CEO of Synchronoss and join the Synchronoss Board. Synchronoss’ current CEO, Stephen Waldis will move into the role of active Executive Chairman of the Board. The firm has institutional ownership of 90.90%, while insider ownership included 6.10%. SNCR attains analyst recommendation of 1.60 with week’s performance of -13.86%. Investors looking further ahead will note that the Price to next year’s EPS is 19.84%.